ELISA News and Research

RSS

HSP27 protein can indicate lung damage during early stages of COPD

Chronic obstructive pulmonary disease (COPD) is a widespread disease. In Austria alone, there are between 500,000 and 600,000 sufferers; around ninety per cent of cases are the result of smoking. Now, under the leadership of Hendrik Jan Ankersmit, a research team from the University Department of Surgery at MedUni Vienna and the Christian Doppler Laboratory for the Diagnosis and Regeneration of Heart and Thorax Diseases has discovered a protein marker in the blood that can already indicate lung damage during the early stages of COPD, before a decrease in lung volume is detected by a pulmonary function test.

5 Apr 2012

CINJ experts available to discuss importance of healthy diet and its role in cancer prevention

March is National Nutrition Month. "Get Your Plate in Shape" is the national theme for this year's month-long reminder that good nutrition is essential for your heath. Throughout the month, experts from The Cancer Institute of New Jersey (CINJ) will be available to discuss the importance of a healthy diet and its role in cancer prevention.

27 Feb 2012

China's SFDA approves Dynex DS2 ELISA analyzer

Dynex Technologies announced today it has received approval from China's State Food and Drug Administration (SFDA) to market the DS2 automated enzyme-linked immunosorbent assay (ELISA) analyzer in China.

From Thermo Fisher Scientific Inc. 22 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.

21 Jan 2012

NanoInk launches new automated protein NanoArray assay platform

The Nano BioDiscovery™ Division of NanoInk®, Inc. announced today the release of a new automated platform for the analysis of its protein NanoArray assays. NanoInk’s NanoArray Assay System™ enables detection, identification, and quantitation of clinically relevant, low abundance proteins from a wide variety of sample types for applications such as biomarker analysis, translational medicine, and toxicology.

10 Jan 2012

Electromechanical wave imaging can diagnose non-periodic arrhythmias

Thanks to a new study from Columbia Engineering School, doctors may now be able to diagnose in their offices non-periodic arrhythmias-noninvasively and at low cost-within a single heartbeat. Non-periodic arrhythmias include atrial and ventricular fibrillation, which are associated with severely abnormal heart rhythm that can in some cases be life-threatening.

9 Dec 2011

Breast cancer drug Avastin loses FDA support

According to a Food and Drug Administration (FDA) announcement last Friday, the cancer drug Avastin should not be used to treat breast cancer that has spread to other organs because it doesn't help patients enough to justify its risky side effects.

21 Nov 2011

First study to evaluate mycoestrogens in young girls

Puberty is a time in a girl's life considered highly sensitive to stimulation by the hormone estrogen and a critical window during which estrogen exposure could greatly influence the risk of breast cancer later in life. An early onset of puberty also has been consistently shown in studies to increase the risk of breast cancer.

2 Nov 2011

Working in shifts associated with elevated levels of stress hormone cortisol

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) found that shift work at a young age is associated with elevated long-term cortisol levels and increased BMI. Previous studies have shown that long-term elevated cortisol levels lead to increased abdominal obesity, hypertension, diabetes and cardiovascular risk.

3 Oct 2011

Researchers to develop diagnostic test for folate receptor autoantibody

Researchers at SUNY Downstate Medical Center have received a $50,000 grant from the SUNY Research Foundation Technology Accelerator Fund to develop a diagnostic test for the folate receptor autoantibody. This autoantibody is associated with neural tube defects, subfertility, cerebral folate deficiency in infants and autism spectrum disorders.

26 Aug 2011

IVAX Diagnostics net revenues decrease 0.4% to $4,375,000 for quarter ended June 30, 2011

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the quarter ended June 30, 2011.

23 Aug 2011

Quanterix's ELISA precisely measures low abundance cytokines in Crohn's disease

Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease.

20 Aug 2011

Diamedix, LABSCO sign distribution agreement for instrumentation systems and test kits

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, announced that Diamedix Corporation, IVAX Diagnostics' wholly-owned subsidiary located in Miami, Florida, has signed a three-year agreement with Laboratory Supply Company, the largest privately held supplier of diagnostic instrumentation and clinical laboratory products to hospitals, physician office laboratories, reference labs and other non-acute care settings in the United States.

4 Aug 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

Randox Drug Residues release newly improved Multi-Sulphonamide Testing Platform

Randox Drug Residues have released their newly improved Antimicrobial Array I. This comprehensive multiplex testing platform allows for the simultaneous detection of 15 of the most commonly abused sulphonamides in food production and agricultural industries.

From Randox Laboratories Ltd. 23 Jun 2011

Free ADAP 2.0 software upgrade with Biochrom's EZ Read 400 research reader

Busy laboratory environments require a microplate reader with the flexibility to cover many assay types, and software that delivers fast, reliable analysis. With this in mind, Biochrom are offering a free software upgrade from ADAP 2.0 Basic to ADAP 2.0 Plus with purchases of the EZ Read 400 research reader until 30 September 2011. For further information, visit www.biochrom.co.uk.

From Biochrom Ltd. 20 Jun 2011

Future Medicinal Chemistry accepted for coverage by MEDLINE

Future Science Ltd announces today that its new journal Clinical Investigation which launched in January 2011 has been selected for coverage by Chemical Abstracts.

17 Jun 2011

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, based in Boston, MA, for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays.

16 Jun 2011